Infliximab discontinuation in patients with ulcerative colitis

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	412-413
Number of pages	2
Journal	The Lancet Gastroenterology and Hepatology
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/S2468-1253(21)00103-5
State	Published - Jun 2021

Access to Document

@article{59080cf886b04ea2b825c409b8ed5781,

title = "Infliximab discontinuation in patients with ulcerative colitis",

author = "Bella Ungar",

note = "Funding Information: I have received lecturer fees and research grants from Takeda, Janssen, AbbVie, and Neopharm.",

year = "2021",

month = jun,

doi = "10.1016/S2468-1253(21)00103-5",

language = "אנגלית",

volume = "6",

pages = "412--413",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Infliximab discontinuation in patients with ulcerative colitis

AU - Ungar, Bella

N1 - Funding Information: I have received lecturer fees and research grants from Takeda, Janssen, AbbVie, and Neopharm.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85106215712&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(21)00103-5

DO - 10.1016/S2468-1253(21)00103-5

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 33887263

AN - SCOPUS:85106215712

SN - 2468-1253

VL - 6

SP - 412

EP - 413

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 6

ER -